JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma

Our partner journal Future Oncology has recently published a Clinical Trial Protocol, which details the Phase II JAVELIN Bladder Medley umbrella trial. The trial is exploring novel combinations with avelumab as first-line maintenance therapy for advanced urothelial carcinoma after first-line chemotherapy (NCT05327530). Abstract Results from JAVELIN Bladder 100 established avelumab (anti–PD-L1) first-line maintenance as the standard-of-care treatment for patients with advanced urothelial carcinoma (UC) that has not progressed with first-line platinum-based chemotherapy. We describe the design of JAVELIN Bladder Medley (NCT05327530), an ongoing Phase II, multicenter, randomized, open-label, parallel-arm, umbrella trial. Overall, 252 patients with advanced UC who are progression-free...